International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman diseaseFrits van Rhee, David C. Fajgenbaum, Peter M. Voorhees et al.|Blood|2018Cited by 421
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C. Fajgenbaum, David Wu, Aaron M. Goodman et al.|American Journal of Hematology|2020Cited by 32
Treatment of relapsed and refractory myelomaDonna Reece, Michael J. Kovacs, Richard LeBlanc et al.|Leukemia & lymphoma/Leukemia and lymphoma|2008Cited by 14